title: Heart failure and chemotherapeutic agents.
abstract: Advances in chemotherapeutic agents over the past two decades have resulted in significantly improved cancer survival rates. Cardiac toxicity, however, has emerged as a leading cause of morbidity, both during and years after treatment. One of the most common manifestations of cardiotoxicity is that of heart failure and left ventricular systolic dysfunction. Consequently, the field of cardio-oncology is a rapidly emerging field of sub-specialty, with growing research interests in all aspects of management. In this review, current opinions and guidelines in this field are discussed, with particular focus on the most common culprits, the anthracyclines and the monoclonal antibody, trastuzumab.
authors.affiliation: Department of Cardiovascular Research, King's College London, The James Black Center, 125 Coldharbour Lane, London SE5 9NU, UK.|Department of Cardiology, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.
authors.forename: Susan
authors.initials: S
authors.lastname: Piper
authors.affiliation: Department of Cardiovascular Research, King's College London, The James Black Center, 125 Coldharbour Lane, London SE5 9NU, UK.|Department of Cardiology, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.
authors.forename: Theresa
authors.initials: T
authors.lastname: McDonagh
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D066126:Cardiotoxicity / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006333:Heart Failure / Q000139:chemically induced* / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D000068878:Trastuzumab / Q000009:adverse effects
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D000068878:Trastuzumab
keywords: anthracyclines; cardiotoxicity; chemotherapy; heart failure; left ventricular systolic dysfunction; trastuzumab